Compare Repligen Corporation Common Stock (RGEN) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Banco Santander SA — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Banco Santander SA trades at $13.61 (market cap $196.48B). The key difference: Banco Santander SA is far larger — about 17.6× Repligen Corporation Common Stock's market cap, and Banco Santander SA pays a 2.14% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Banco Santander SA for 55 Days on average.
| RGEN | SAN | |
|---|---|---|
Market Cap | $11.14B | $196.48B |
Volume | 1,259,263 | 9,811,951 |
Sector | Health | Financials |
52-Week High | $194.57 | $15.05 |
52-Week Low | $102.87 | $9.65 |
Typical Hold Time | 0 Days | 55 Days |
Enterprise Value | $11.02B | $362.68B |
Dividend Yield | — | 2.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Banco Santander (SAN) trades at $13.41, down 0.52% on the day, with a bearish technical signal from moving averages and a mixed earnings history including a Q1 2026 beat. The company maintains strong profitability with a 26.25% net income margin and a 16.07% ROE, supported by record profits highlighted in recent earnings calls. Recent developments include the completion of the Webster acquisition, expanding its U.S. presence, and a dividend payment scheduled for November 2026.
The outlook is cautiously optimistic with analyst consensus at 'Moderate Buy' (64% buy ratings), but risks include declining cash flows from operations and rising debt-to-asset ratios. Revenue growth is projected to reach $61.9B in 2026, though net cash flow turned negative in 2024-2025, signaling potential liquidity pressures. Investors should weigh strong profitability against financial leverage and integration risks from acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
